A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

NCT04576117 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

300

Enrollment

NIH

Sponsor class

Conditions

Recurrent Low Grade Astrocytoma
Recurrent WHO Grade 2 Glioma
Refractory Low Grade Astrocytoma
Refractory Low Grade Glioma
Refractory WHO Grade 1 Glioma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Magnetic Resonance Imaging
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
DRUG: Selumetinib Sulfate
DRUG: Vinblastine Sulfate

Sponsor

National Cancer Institute (NCI)